This document provides the first expert consensus recommendations for the clinical use and future investigation of the Magmaris bioresorbable scaffold upon its commercial launch.
Guides responsible Magmaris scaffold introduction in practice; extends BRS evidence with device-specific consensus and prioritized research.
Bioresorbable scaffolds represent an exciting milestone in the development of coronary stent technology with the potential to substantially improve the management of patients with coronary artery disease. In an attempt to provide first recommendations for the technology, experienced experts involved in the first-in-man studies met in Zurich on the 14 April 2016 in order to reach consensus on a responsible market introduction. This document will be updated regularly as new information from clinical trials becomes available and should be understood as a review of current data, opportunities, expectations, advice, and recommendations for future investigations.
No takes yet. Share an insight, caveat, or question.
Fajadet et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: